Varanasi News Magazine

Acral Lentiginous Melanoma Market to Witness Growth by (2022-2032), Estimates DelveInsight | Key Companies – Atreca, Bristol-Myers Squibb, Pfizer, Novartis

 Breaking News
  • No posts were found

Acral Lentiginous Melanoma Market to Witness Growth by (2022-2032), Estimates DelveInsight | Key Companies – Atreca, Bristol-Myers Squibb, Pfizer, Novartis

September 20
22:31 2022
Acral Lentiginous Melanoma Market to Witness Growth by (2022-2032), Estimates DelveInsight | Key Companies - Atreca, Bristol-Myers Squibb, Pfizer, Novartis
DelveInsight’s “Acral Lentiginous Melanoma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Acral Lentiginous Melanoma, historical and forecasted epidemiology as well as the Acral Lentiginous Melanoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Acral Lentiginous Melanoma market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Acral Lentiginous Melanoma pipeline products will significantly revolutionize the Acral Lentiginous Melanoma market dynamics.  

 

Acral Lentiginous Melanoma Overview

According to AIM at Melanoma Foundation, Acral Lentiginous Melanoma (ALM) is a type of melanoma that appears on the palms of the hands, the soles of the feet, or under the nails. The term “acral” refers to the occurrence of melanoma on the palms or soles. The word“lentiginous” means that the spot of melanoma is much darker than the surrounding skin; it has a sharp border between the dark skin and the lighter skin around it. The contrast in color is one of the most noticeable symptoms of acral lentiginous melanoma.

Acral Lentiginous Melanoma starts as a slowly-enlarging flat patch of discolored skin. At first, the malignant cells remain within the epidermis—the in situ phases of melanoma, which can persist for months or year.

 

Some of the key facts of the Acral Lentiginous Melanoma Market Report: 

  • The Acral Lentiginous Melanoma market size is anticipated to grow with a significant CAGR during the study period (2019-2032) 
  • Acral Lentiginous Melanoma, is most commonly diagnosed in people over age 40, and affects men and women of all skin colors equally. It is the fourth most common subtype of melanoma, with an estimated frequency of 2‒5% of all melanomas 
  • According to the study conducted by Bradford et al. titled “Acral lentiginous melanoma: Incidence and survival patterns in the United States,” the overall age-adjusted incidence rate was 1.8 per million persons. 
  • Key Acral Lentiginous Melanoma Companies: Atreca, Bristol-Myers Squibb, Pfizer, Novartis, and others 
  • Key Acral Lentiginous Melanoma Therapies: ATRC-101, Nivolumab with Ipilimumab, Sunitinib, Imatinib, and others 
  • The Acral Lentiginous Melanoma epidemiology based on gender analyzed that, Acral Lentiginous Melanoma is equally common in males and females

 

Get a Free sample for the Acral Lentiginous Melanoma Market Report 

 

Key benefits of the Acral Lentiginous Melanoma Market report:

  1. Acral Lentiginous Melanoma market report covers a descriptive overview and comprehensive insight of the Acral Lentiginous Melanoma Epidemiology and Acral Lentiginous Melanoma market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. The Acral Lentiginous Melanoma market report provides insights on the current and emerging therapies.
  3. Acral Lentiginous Melanoma market report provides a global historical and forecasted market covering drug outreach in 7MM.
  4. The Acral Lentiginous Melanoma market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Acral Lentiginous Melanoma market.

 

Discover more about therapies set to grab major Acral Lentiginous Melanoma market share @ Acral Lentiginous Melanoma market forecast 

 

Acral Lentiginous Melanoma Epidemiology Segmentation:

The Acral Lentiginous Melanoma market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Acral Lentiginous Melanoma
  • Prevalent Cases of Acral Lentiginous Melanoma by severity
  • Gender-specific Prevalence of Acral Lentiginous Melanoma
  • Diagnosed Cases of Episodic and Chronic Acral Lentiginous Melanoma 

 

Acral Lentiginous Melanoma Market  

The dynamics of the Acral Lentiginous Melanoma market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as ATRC-101, Nivolumab with Ipilimumab, and others during the forecasted period 2019-2032. 

 

Download the report to understand which factors are driving Acral Lentiginous Melanoma epidemiology trends @ Acral Lentiginous Melanoma Epidemiological Insights

 

Acral Lentiginous Melanoma Therapies and Key Companies

  • ATRC-101: Atreca
  • Nivolumab with Ipilimumab: Bristol-Myers Squibb
  • Sunitinib: Pfizer
  • Imatinib:  Novartis
  • Tebentafusp: AstraZeneca 

 

Scope of the Acral Lentiginous Melanoma Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Acral Lentiginous Melanoma Companies: Atreca, Bristol-Myers Squibb, Pfizer, Novartis, and others
  • Key Acral Lentiginous Melanoma Therapies: ATRC-101, Nivolumab with Ipilimumab, Sunitinib, Imatinib, and others
  • Acral Lentiginous Melanoma Therapeutic Assessment: Acral Lentiginous Melanoma current marketed and Acral Lentiginous Melanoma emerging therapies
  • Acral Lentiginous Melanoma Market Dynamics:  Acral Lentiginous Melanoma market drivers and barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Unmet Needs, KOL’s views, Analyst’s views, Acral Lentiginous Melanoma  Market Access and Reimbursement

 

Table of Contents 

1. Acral Lentiginous Melanoma Market Report Introduction

2. Executive Summary for Acral Lentiginous Melanoma

3. SWOT analysis of Acral Lentiginous Melanoma

4. Acral Lentiginous Melanoma Patient Share (%) Overview at a Glance

5. Acral Lentiginous Melanoma Market Overview at a Glance

6. Acral Lentiginous Melanoma Disease Background and Overview

7. Acral Lentiginous Melanoma Epidemiology and Patient Population

8. Country-Specific Patient Population of Acral Lentiginous Melanoma 

9. Acral Lentiginous Melanoma Current Treatment and Medical Practices

10. Acral Lentiginous Melanoma Unmet Needs

11. Acral Lentiginous Melanoma Emerging Therapies

12. Acral Lentiginous Melanoma Market Outlook

13. Country-Wise Acral Lentiginous Melanoma Market Analysis (2019–2032)

14. Acral Lentiginous Melanoma Market Access and Reimbursement of Therapies

15. Acral Lentiginous Melanoma Market drivers

16. Acral Lentiginous Melanoma Market barriers

17.  Acral Lentiginous Melanoma Appendix

18. Acral Lentiginous Melanoma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

To know more about Acral Lentiginous Melanoma treatment, visit @ Acral Lentiginous Melanoma Medications

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/